Screener
Discontinued — last reported Q4 '23
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Pacific Biosciences of California’s 10-K, filed February 28, 2024.
- Filed
- Feb 28, 2024
- Fiscal year
- FY2023
- Accession
- 0001299130-24-000054
| (in thousands, except per share amounts) | Years Ended December 31, 2023 | Years Ended December 31, 2022 | Years Ended December 31, 2021 |
|---|---|---|---|
| Sales, general and administrative | 169,818 | 160,854 | 124,124 |
| Merger-related expenses | 9,042 | — | 31,129 |
| Change in fair value of contingent consideration | 15,060 | 2,377 | 1,143 |
| Amortization of acquired intangible assets | 6,157 | — | — |
| Total operating expense | 387,247 | 356,231 | 269,295 |
| Operating loss | (334,467) | (307,196) | (210,435) |
| Loss from Continuation Advances from Illumina | — | — | (52,000) |
| Loss on extinguishment of debt | (2,033) | — | — |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Pacific Biosciences of California's D&A?
- Pacific Biosciences of California (PACB) reported D&A of $1.54M in Q4 2023.
- How has Pacific Biosciences of California's D&A changed year-over-year?
- Pacific Biosciences of California's D&A increased by 122.2% year-over-year, from -$6.94M to $1.54M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Pacific Biosciences of California's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude